Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for L&K Biomed Co., Ltd. (156100:KRX), powered by AI.
L&K Biomed Co., Ltd. is currently trading at ₩5,230. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for L&K Biomed Co., Ltd. on Alpha Lenz.
L&K Biomed Co., Ltd.'s P/E ratio is -7.2.
“L&K Biomed Co., Ltd. trades at a P/E of -7.2 (undervalued) with modest ROE of -37.0%. 3Y revenue CAGR of 25.3% highlights clear growth momentum.”
Ask for details →L&K Biomed Co., Ltd. is a prominent player in the medical technology sector, specializing in the development and production of innovative orthopedic solutions. At the core of its operations, the company focuses on the design and manufacture of spinal implant devices. These products are crucial in addressing spinal disorders and enhancing patient mobility, making significant impacts in the healthcare industry. L&K Biomed’s offerings are characterized by cutting-edge technology, ensuring the advancement of medical procedures and patient outcomes. The company operates within a highly specialized niche, catering to a global clientele that includes hospitals, medical centers, and surgical specialists. Its dedication to research and development supports continuous innovation, ensuring that L&K Biomed remains at the forefront of medical technology solutions. By leveraging advanced materials and pioneering surgical techniques, the company plays a vital role in the ever-evolving landscape of orthopedic treatments. L&K Biomed Co., Ltd. is strategically positioned to influence the market with its commitment to quality and innovation, underscoring its significance within the healthcare technology industry.
“L&K Biomed Co., Ltd. trades at a P/E of -7.2 (undervalued) with modest ROE of -37.0%. 3Y revenue CAGR of 25.3% highlights clear growth momentum.”
Ask for details →L&K Biomed Co., Ltd. (ticker: 156100) is a company listed on KRX in the Healthcare sector (Medical Devices). It has approximately 91 employees. Market cap is $116.9B.
The current price is ₩5,230 with a P/E ratio of -7.17x and P/B of 2.57x.
ROE is -37.05% and operating margin is 1.84%. Annual revenue is $38.9B.